Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07652515 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer

Name: A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer — clinical trial record (NCT07652515)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorGlaxoSmithKline

Started2026-08-17

View on ClinicalTrials.gov ↗

This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).

Trial Details

NCT Number	NCT07652515
Lead Sponsor	GlaxoSmithKline
Conditions	Neoplasms, Endometrial
Enrollment	100 participants
Start Date	2026-08-17
Primary Completion	2030-08-30 (estimated)
Study Completion	2030-08-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-17